Mammalian Peroxiredoxin Isoforms Can Reduce Hydrogen Peroxide Generated in Response to Growth Factors and Tumor Necrosis Factor-alpha *

Sang Won KangDagger , Ho Zoon ChaeDagger §, Min Seok SeoDagger , Kanghwa KimDagger par , Ivan C. Baines**Dagger Dagger , and Sue Goo RheeDagger §§

From the Dagger  Laboratory of Cell Signaling and ** Laboratory of Cell Biology, NHLBI, National Institutes of Health, Bethesda, Maryland 20892

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Mammalian tissues express three immunologically distinct peroxiredoxin (Prx) proteins (Prx I, II, and III), which are the products of distinct genes. With the use of recombinant proteins Prx I, II, and III, all have now been shown to possess peroxidase activity and to rely on Trx as a source of reducing equivalents for the reduction of H2O2. Prx I and II are cytosolic proteins, whereas Prx III is localized in mitochondria. Transient overexpression of Prx I or II in cultured cells showed that they were able to eliminate the intracellular H2O2 generated in response to growth factors. Moreover, the activation of nuclear factor kappa B (NFkappa B) induced by extracellularly added H2O2 or tumor necrosis factor-alpha was blocked by overproduction of Prx II. These results suggest that, together with glutathione peroxidase and catalase, Prx enzymes likely play an important role in eliminating peroxides generated during metabolism. In addition, Prx I and II might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentration of H2O2.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

We have previously purified a 25-kDa thioredoxin peroxidase (TPx)1 from Saccharomyces cerevisiae that reduces hydroperoxides with thioredoxin (Trx) as an immediate electron donor (1-7). A data base search revealed more than 40 proteins from a wide variety of species that show sequence similarity to yeast TPx (8, 9). These homologous proteins were named the peroxiredoxin (Prx) family (8, 9). They were not termed the TPx family because not all members use Trx as the hydrogen donor (10, 11).2 The Prx family includes 12 mammalian proteins that were identified without reference to peroxidase activity but rather in association with a variety of diverse cellular functions including proliferation, differentiation, and immune response (12-24). Whether any of these mammalian Prx proteins possess peroxidase activity and, if so, the identity of the immediate electron donors both remain unknown. As will be published elsewhere, the mammalian Prx members can be divided into three distinct groups (Prx I, II, and III) on the basis of their amino acid sequences and immunological properties.3

We have now shown that recombinant proteins from each of the three groups were able to reduce peroxides with the use of electrons from Trx. However, unlike the situation with other enzymes that use Trx, glutaredoxin (Grx) could not replace Trx as the electron donor. In addition, we showed that the mammalian Prx enzymes are capable of reducing H2O2 produced in cells stimulated with growth factors and of inhibiting NFkappa B activation induced by H2O2 or tumor necrosis factor-alpha (TNF-alpha ), indicating that they function as peroxidases inside cells and possibly serve as components of the signaling cascades by growth factors and TNF-alpha in which H2O2 acts as an intracellular messenger.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Glutamine synthetase was purified from Escherichia coli as described (1). Rabbit antisera to human Prx I and Prx II were generated against recombinant proteins prepared as described below. Antiserum to Prx III proteins was generated by immunizing rabbits with a keyhole limpet hemocyanin-conjugated peptide (SPTASKEYFEKVHQ) that corresponds to a sequence in the COOH-terminal region of mouse Prx III.

Cloning and Expression in E. coli of Prx I, II, and III cDNAs-- Complementary DNAs corresponding to Prx I, II, and III proteins were obtained by the polymerase chain reaction (PCR) with Taq polymerase (Perkin Elmer). A cDNA library derived from human myelogenous leukemia K562 cells (CLONTECH) served as the template source for amplification of Prx I and II cDNAs. Prx III cDNA was amplified from a cDNA library prepared from mouse erythroleukemia C19 cells (CLONTECH). Because Prx III matured in mitochondria lacks the NH2-terminal 63 amino acids (13, 19), the forward primer was designed to amplify from Pro64 and to include an additional Met at the new NH2 terminus. The forward primers for Prx I (5'-ATACATATGTCTTCAGGAAATGCTAAAAT-3'), Prx II (5'-ATACATATGGCCTCCGGTAACGCGCGCATCG-3'), and Prx III (5'-TACATATGCCTGCTGTCACCCAGCACG-3') contain an NdeI site (underlined) and the initiation codon (italicized). The reverse primers for Prx I (3'-TCTTATAAAGAGGTTCGTCTTCACTCCTAGGTTA-5'), Prx II (3'-TCCTTATAAAGAGGTTTGTGTTAATCCCTAGGTTA-5'), and Prx III (3'-CTCTTCCAGGTAGTCATCCTAGGTAG-5') contain a BamHI site (underlined) and the stop codon (italicized). The PCR products were purified with PCR Select III (5 Prime right-arrow 3 Prime, Inc., Boulder, CO) and subcloned into the pGEM-T vector (Promega). The identity of all PCR products was confirmed by nucleotide sequencing with an automated fluorescent dye DNA sequencer (Applied Biosystems, model 370A).

Each of the NdeI-BamHI fragments from pGEM-T was transferred to the pET-17b plasmid (Novagen) to generate pETprxI, pETprxII, and pETprxIII. An E. coli strain was transfected separately with each of these three plasmids and recombinant Prx I, II, and III proteins were purified from these transfected strains.

Preparation of Trx, Grx, Trx Reductase (TR), and Glutathione Reductase (GR)-- Rat Trx cDNA (25) was obtained by PCR amplification with a forward primer containing an NdeI site and the initiation codon, and a reverse primer containing a BamHI site and the stop codon. Cloning of the PCR product into pGEM-T and pET-17b as well as subsequent expression in E. coli were performed basically as described above for the Prx proteins. Recombinant Trx was purified by heat treatment at 65 °C and sequential chromatography on Sephacryl S-100 HR gel filtration and HPLC DEAE-5PW ion exchange columns. The NH2-terminal amino acid sequence of the recombinant protein was confirmed by automated Edman degradation. Grx, GR, and TR were purified from rat liver as described (26, 27).

Determination of Protein Concentration-- The concentrations of Prx I, II, and III and Trx were determined spectrophotometrically with absorptivity (A0.1%) at 280 nm values of 0.815, 0.938, 0.825, and 0.738, respectively; these values were calculated on the basis of the amino acid composition of the proteins deduced from the corresponding cDNA sequences. Because the sequences of rat Grx, GR, and TR are not available, the concentrations of these proteins were determined with the BCA protein assay reagent (Pierce) and bovine serum albumin as standard.

Subcellular Fractionation-- Subcellular fractions of A431 cells were prepared by differential centrifugation (28, 29). Briefly, cells were transferred at a density of 3 × 106 cells to a 150-mm dish, allowed to recover for 24 h, and then incubated for 18 h in Dulbecco's modified Eagle's medium supplemented with 0.5% fetal bovine serum. Cells were washed with and scraped into ice-cold phosphate-buffered saline, and separated by centrifugation at 500 × g for 5 min. For preparation of organelles, they were then resuspended in buffer A (10 mM Hepes-NaOH (pH 7.0), 5 mM MgCl2, 15 mM KCl, 1 mM phenylmethylsulfonyl fluoride, leupeptin (5 µg/ml), and aprotinin (5 µg/ml)) at a density of 1 × 107 cells/ml and allowed to swell for 10 min at 4 °C. Cells were homogenized gently with a Dounce homogenizer until disruption, which was monitored by assaying the activity of released lactate dehydrogenase, was achieved. The cell homogenate was immediately mixed with an equal volume of buffer A containing 0.5 M sucrose. Nuclei and unbroken cells were separated by centrifugation at 500 × g for 10 min. After adding EDTA to a final concentration of 10 mM, the supernatant was centrifuged at 16,000 × g for 10 min. The resulting particulate fraction was suspended in buffer A containing 0.25 M sucrose, recentrifuged, dissolved in lysis buffer (20 mM Hepes-NaOH (pH 7.2), 1% Triton X-100, 10% (v/v) glycerol, 1 mM phenylmethylsulfonyl fluoride, leupeptin (5 µg/ml), and aprotinin (5 µg/ml)) to a final volume of 1 ml, and sonicated to obtain the organelle extract. The 16,000 × g supernatant from the previous step was centrifuged at 100,000 × g for 1 h, and the resulting supernatant was designated the cytosolic fraction.The pellet was washed once with buffer A containing 0.25 M sucrose, dissolved in 1 ml of lysis buffer, and designated the membrane fraction.

For the preparation of nuclei, cells were resuspended at a density of 1 × 107/ml in buffer A containing 0.1% Nonidet P-40, and then homogenized as described above. Nuclei were isolated by centrifugation of the homogenate at 500 × g for 10 min. Contamination of the nuclear pellet by unbroken cells was ruled out by confirming the absence of lactate dehydrogenase. Nuclei were resuspended in 1 ml of buffer A containing 0.25 M sucrose, recentrifuged at 500 × g for 10 min, adjusted to a final volume of 1 ml with lysis buffer, and sonicated to yield the crude nuclear extract.

Portions of each subcellular fraction were separated by SDS-polyacrylamide gel electrophoresis and assayed for Prx and marker proteins (catalase and histone for organelles and nuclei, respectively) by immunoblot analysis.

Construction of Prx I and Prx II Eukaryotic Expression Vectors-- Prx I and II coding sequences were prepared by PCR from pETprxI and pETprxII, respectively. The forward primers, which include the initiation codon (italicized), were 5'-GGGGCCAAGCTTATGTCTTCAGGAAATGCTAA-3' for Prx I and 5'-TTCAAAAAGCTTATGGCCTCCGGTAACGCGCG-3' for Prx II. The reverse primers, which include the stop codon (italicized), were 5'-CGGGCCTCTAGATCACTTCTGCTTGGAGAAAT-3' for Prx I and 5'-GGCCCCTCTAGACTAATTGTGTTTGGAGAAA-3' for Prx II. The PCR products were subcloned into pCR3.1TM basic vector (Invitrogen) to yield pCRprxI, and pCRprxII. Clones containing the coding sequences in the correct orientation were selected and used for transfection.

Transfection of Eukaryotic Cells-- NIH 3T3 and A431 cells were plated at a density of 3 × 105 per 60-mm dish and allowed to recover for 24 h. They were then incubated with 4 µg of appropriate DNA and 20 µl of LipofectAMINETM in 3 ml of opti-MEM (Life Technologies, Inc.) for 6 h, after which 3 ml of Dulbecco's modified Eagle's medium containing 20% fetal bovine serum (A431 cells) or calf serum (NIH 3T3 cells) were added to the transfection mixture and the cells were incubated for an additional 18 h. The medium was then aspirated and cells were incubated for 18 h in fresh Dulbecco's modified Eagle's medium containing 0.5% proper serum before assays of H2O2 generation. HeLa cells were plated at a density of 4 × 105 per 60-mm dish, and 24 h after plating, cells were transfected with the indicated amount of appropriate DNA using Superfect (QIAGEN) for 3 h and further incubated in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum for 21 h before stimulation with TNF-alpha or H2O2. The efficacy and reproducibility of transfection were confirmed by immunoblot analysis of the target protein in each batch of cells.

Assay of Intracellular H2O2 Generation-- Intracellular H2O2 generation was measured with a fluorescent dye, 2',7'-dichlorofluorescein diacetate (DCFH-DA), as described (30). Briefly, serum-deprived transfected NIH 3T3, A431, and HeLa cells were stimulated for 10 min with platelet-derived growth factor (PDGF)-AB (5 ng/ml), 5 min with epidermal growth factor (EGF) (500 ng/ml), or 5 min with H2O2 (10 µM), respectively, in minimum Eagle's medium without phenol red, rapidly washed once with Krebs-Ringer solution, and then incubated in Krebs-Ringer solution containing DCFH-DA (5 µg/ml). DCFH-DA is nonpolar and readily diffuses into cells, where it is hydrolyzed to the nonfluorescent polar derivative DCFH and thereby trapped within the cells. In the presence of H2O2, DCFH is oxidized to the highly fluorescent 2',7'-dichlorofluorescein (DCF). Culture dishes were sealed with paraffin film and placed in a CO2 incubator at 37 °C for 5 min, after which DCF fluorescence was measured with a Zeiss Axiovert 135 inverted microscope equipped with a X20 Neoflur objective and Zeiss LSM410 confocal attachment. To avoid photooxidation of DCFH, we collected the fluorescent image with a single rapid scan (4-line average; total scan time, 4.33 s) and identical parameters such as contrast and brightness for all samples. The cells were then examined by differential interference contrast microscopy. Five groups of 10-20 subconfluent cells or 20-30 confluent cells were randomly selected from the image for each sample, the fluorescence intensity was measured for each group from the fluorescence image, and the relative fluorescence intensity per cell was obtained from the average of the five group values.

Chloramphenicol Acetyltransferase (CAT) Assay-- HeLa cells that had been plated 24 h prior to transfection at 4 × 105 cells per 60-mm dish were transfected with a reporter plasmid, pNFkappa BCAT (6 µg) plus the indicated amount of either pCR or pCRprxII. The reporter plasmid pNFkappa BCAT containing a CAT reporter gene placed under the control of four NFkappa B enhancer sites has been described.4 After stimulation with H2O2 or TNF-alpha , cells were washed, scraped in phosphate-buffered saline, and harvested by centrifugation for 5 min at 1000 × g. The resulting pellet was suspended in 150 µl of 0.25 M Tris-HCl (pH 7.4) and disrupted by repeating the freezing and thawing three times. The relative amount of CAT in 20 µg of cell extract was measured using the enzyme-linked immunosorbent assay kit (Boehringer Mannheim).

Gel Mobility Shift Assay-- HeLa cell nuclear extracts were prepared as described (31). Nuclear extracts were incubated with a 32P-labeled kappa B DNA probe (105 cpm) in the presence of 0.5 µg poly(dI-dC). After 30 min at room temperature, the bound and unbound oligonucleotides were separated on a 5% polyacrylamide gel. For the competition experiment, 50-fold molar excess of unlabeled oligonucleotides were included. The 32P-labeled and unlabeled oligonucleotides with the kappa B binding site were as described (32) and kindly provided by Dr. Kuan-Teh Jeang (NIAID, NIH).

Data Presentation-- With the exception of those shown in Figs. 3 (C and D) and 4B, data presented are from representative experiments that were repeated at least three times with similar results.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Peroxidase Activity of Mammalian Prx Proteins-- We have previously shown that yeast TPx reduces peroxides with the use of electrons provided by the Trx system (Trx, TR, and NADPH) (5). We therefore examined mammalian Prx proteins for peroxidase activity toward H2O2 in the presence of the Trx system or the Grx system (Grx, glutathione, GR, and NADPH), using recombinant Prx proteins from E. coli. The rate of H2O2 degradation was measured by monitoring the decrease in A340 attributable to the oxidation of NADPH. Prx I, II, and III proteins each catalyzed the H2O2-dependent oxidation of NADPH in the presence of the Trx system (Fig. 1). The oxidation of NADPH required all three protein components (Prx, Trx, and TR), being negligible in the absence of any one of the three. In contrast, none of the three Prx enzymes increased the H2O2-dependent oxidation of NADPH in the presence of the Grx system. Neither increasing the concentrations of Grx from 2.2 to 8.8 µM, glutathione from 2 to 4 mM, or GR from 46 to 92 nM, nor varying the pH from 7.0 to 8.0, affected the inability of the Grx system to support the peroxidase activity of Prx I, II, or III. The functional efficacy of the Grx and GR preparations was demonstrated by measuring their glutathione-disulfide transhydrogenase (33) and glutathione peroxidase (34) activities, respectively. Thus, the three mammalian Prx proteins appear to receive reducing equivalents specifically from Trx and TR.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   The rate of H2O2 reduction catalyzed by Prx enzymes in the presence of the Trx or Grx systems. The initial rate of NADPH oxidation was monitored spectrophotometrically in the absence (control) or presence of Prx (Prx I, II, or III) at 37 °C. The 150-µl reaction mixture contained 50 mM Hepes-NaOH (pH 7.0), 250 µM NADPH, 0.52 µM Prx protein, and either 46 nM TR and 2.2 µM Trx (Trx system) or 46 nM GR, 2.2 µM Grx, and 2 mM glutathione (Grx system). The reaction was initiated by the addition of 0.5 mM H2O2.

Subcellular Localization of Prx Isoforms-- Rabbit antibodies were generated against Prx I, II, and III proteins and shown to be specific for the corresponding isoform (not shown). With these isoform-specific antibodies, we investigated the subcellular localization of Prx enzymes by immunoblot analysis of nuclear, organelle, cytosolic, and membrane fractions of A431 human epidermoid carcinoma cells (Fig. 2). Catalase and histone were chosen as markers of organelle and nuclear fractions, respectively. Prx I and II were detected only in the cytosolic fraction, whereas Prx III was apparent as a strong band in the organelle fraction and as a weaker band in the cytosolic fraction. This weaker band is likely attributable to breakage of organelles because catalase, which is localized in peroxisomes, was also detected in the cytosolic fraction. This result is consistent with the fact that SP22 was identified as a substrate of a mitochondrial protease (19).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2.   Subcellular localization of Prx isoforms. Subcellular fractions prepared from A431 cells were subjected to immunoblot analysis with antibodies to catalase (A), histone (B), Prx I (C), Prx II (D), or Prx III (E). Lane 1, total homogenate; lane 2, nuclear fraction; lane 3, organelle fraction; lane 4, cytosolic fraction; and lane 5, membrane fraction.

Removal by Prx Enzymes of Intracellular H2O2 Generated in Response to PDGF or EGF-- Intracellular generation of H2O2 can be monitored with the oxidation-sensitive fluorescent probe DCFH-DA and confocal microscopy. As shown previously (35, 36), exposure of quiescent NIH 3T3 cells to PDGF (5 ng/ml) or A431 cells to EGF (500 ng/ml) resulted in a rapid increase in DCF fluorescence with the maximal effect apparent 10 or 5 min, respectively, after stimulation; fluorescence returned to baseline values after 30 min for both cell types (data not shown). Although many cellular oxidants can oxidize DCFH, H2O2 was shown to be primarily responsible for this reaction on the basis that incorporation of catalase into cells prevented the growth factor-induced increase in DCF fluorescence (35, 36).

We investigated whether Prx family members are able to eliminate H2O2 produced in response to growth factors by transiently expressing Prx I or II in NIH 3T3 cells and Prx II in A431 cells. The overexpression of the two proteins in transfected cells was confirmed by immunoblot analysis (Fig. 3A). We also attempted to express Prx I in A431 cells, but, for an unknown reason, no substantial increase in the amount of this protein was apparent in transfected cells in three independent experiments. In response to stimulation with PDGF (10 min) or EGF (5 min), DCF fluorescence increased more than 2-fold in NIH 3T3 or A431 cells transfected with vector alone. However, overexpression of Prx I or II prevented the growth factor-induced increase in DCF fluorescence (Fig. 3, B-D).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of Prx overexpression on growth factor-induced H2O2 generation. Panel A, NIH 3T3 and A431 cells were transiently transfected with the indicated expression plasmids, and the extent of Prx expression was measured by immunoblot analysis. Panel B, DCF fluorescence was measured with a confocal microscope after incubation of A431 cells in the presence of EGF for 5 min. Panel C, from the images shown in panel B, relative fluorescence intensity per cell was calculated as describe under "Experimental Procedures." Panel D, the transfected NIH 3T3 cells were stimulated with PDGF for 10 min, and the DCF fluorescence was measured. Data in panels C and D are means ± S.E. of the values obtained from five groups of 20-30 cells; pCR represents the vector alone without any insert.

Inhibition of NFkappa B Activation by Prx II Overexpression-- A large number of extracellular stimuli that activate the transcriptional factor NFkappa B are known to do so by producing intracellular H2O2 (37-39). In the cytosol, NFkappa B is in an inactive form bound to an inhibitory subunit, Ikappa B. Activation of cells with appropriate stimuli results in phosphorylation of Ikappa B followed by its selective degradation, thereby allowing free NFkappa B to translocate to nucleus (40). Extracellularly added H2O2 also results in the activation of NFkappa B in HeLa cells (37, 41). We investigated whether overproduction of Prx II can inhibit the H2O2-induced NFkappa B activation (Fig. 4). The overproduction of Prx II in HeLa cells transfected with Prx II-expressing vector, pCRprxII was confirmed by immunoblot analysis (Fig. 4A). The level of PrxII expression was not affected by a 6 h exposure to H2O2 (100 µM). The intracellular peroxidase function of overproduced Prx II was demonstrated by the fact that the H2O2-induced increase in DCF fluorescence was completely prevented by overexpression of Prx II (Fig. 4B). One way to measure NFkappa B activity is to assay the expression of CAT reporter gene under the control of NFkappa B sites. HeLa cells were transiently co-transfected with pCRprxII or control vector pCR and a plasmid (pNFkappa BCAT) containing four NFkappa B enhancer sites and a CAT gene. H2O2 increased CAT expression in cells transfected with pCR but not in cells transfected with pCRprxII (Fig. 4C). For an unknown reason, the level of H2O2-induced CAT expression in Prx II-overexpressing cells was lower than that in control cells.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of Prx II overproduction on H2O2-induced NFkappa B activation in HeLa cells. A, HeLa cells were transiently transfected with 6 µg of control (pCR) and Prx II-expressing (pCRprxII) vectors, and the extent of Prx II expression was measured by immunoblot analysis before and after treatment with 100 µM H2O2 for 6 h. B, relative DCF fluorescence intensity per cell was measured with a confocal microscope after incubation of HeLa cells in the presence of 10 µM H2O2 for 5 min. Data are means ± S.E. of the values obtained from five groups of 20-30 cells. C, relative amounts of CAT were measured in the extracts of cells treated with 100 µM H2O2 for 6 h and expressed as fold activation compared with the amount from pCR-transfected cells. D, DNA-binding activity of NFkappa B in the nuclear extract of HeLa cells treated with 100 µM H2O2 for 30 min was measured by gel mobility shift assay using 32P-labeled oligonucleotides with the kappa B binding site. After separation of bound and unbound oligonucleotides on a 5% polyacrylamide gel, the gel was subjected to autoradiogrphy. Shown here are the NFkappa B-bound DNA bands. E, relative amounts of Ikappa B in the extract of HeLa cells treated with 100 µM H2O2 for 30 min were measured by immunoblot analysis using rabbit serum against Ikappa B (Biotechnology, Inc., Santa Cruz).

The effect of Prx II overexpression on the activation of NFkappa B by H2O2 was also analyzed by gel mobility shift assay using radiolabeled DNA containing NFkappa B-binding sites. The NFkappa B-specific band was evident when nuclear extracts from HeLa cells were incubated with labeled DNA and separated on a gel, and the same band was eliminated by the addition of an excess of unlabeled NFkappa B DNA to the binding mixture (not shown). As shown in Fig. 4D, a 30-min treatment of control cells with H2O2 (100 µM) enhanced the intensity of NFkappa B-specific band. In contrast, when Prx II-overexpressing cells were similarly treated, the band intensity was significantly reduced, suggesting that removal of intracellular H2O2 by Prx II resulted in depletion of nuclear NFkappa B activity. The reason for the reduction of activity below that of untreated cells is unclear. Overexpression of Prx II did not affect the NFkappa B binding activity in cells not treated with H2O2. In another experiment, we evaluated the effect of Prx II overexpression on the degradation of Ikappa B. As shown in Fig. 4E, a 30-min treatment of control cells with 100 µM H2O2 resulted in a significant degradation of Ikappa B and the degradation was partly prevented by overexpression of Prx II.

TNF-alpha is known to activate NFkappa B in HeLa cells by generating intracellular H2O2 (37-41). We tested the ability of PrxII to block the TNF-alpha -induced NFkappa B activation in HeLa cells co-transfected with pNFkappa BCAT and pCR or pNFkappa BCAT and a range of different quantities of pCRprxII. We confirmed that we could overexpress Prx II at several different levels by immunoblot analysis (Fig. 5A). TNF-alpha increased CAT expression in cells transfected with the control vector pCR. But in cells transfected with pCRprxII, the CAT response to TNF-alpha gradually decreased as the amount of overexpressed Prx II increased (Fig. 5B). We also measured NFkappa B activity in nuclear extracts of control and Prx II-overexpressing HeLa cells by gel mobility shift assay (Fig. 5C). The intensity of the NFkappa B-specific band was increased in control cells treated with TNF-alpha (15 ng/ml) but not in similarly treated Prx II-overexpressing cells. These results suggest that overexpression of Prx II prevented the TNF-alpha -induced NFkappa B activation by removing H2O2.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of Prx II overexpression on TNF-alpha -induced NFkappa B activation. Panel A, HeLa cells were transiently transfected with 5 µg of pCR or the indicated amount of pCRprxII (total amount of plasmid was adjusted to 5 µg by adding pCR) and the extent of Prx II expression was measured by immunoblot analysis. Panel B, after stimulation of the transfected cells (from panel A) with TNF-alpha (15 ng/ml) for 6 h, relative amounts of CAT were measured in their extracts and expressed as fold activation compared with the amount from pCR-transfected cells. Panel C, HeLa cells were transiently transfected with 5 µg of pCR and pCRprxII and DNA-binding activity of NFkappa B in the nuclear extract of HeLa cells treated with TNF-alpha (15 ng/ml) for 30 min was measured by gel mobility shift assay as described in the legend to Fig. 4.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Our data suggest that like yeast TPx, all three mammalian Prx proteins reduce H2O2 with reducing equivalents provided by the Trx system. Trx and Grx mediate electron transfer through a simple mechanism that includes the reversible oxidation of two vicinal Cys-SH groups to form a disulfide bond (43, 44). Several oxidoreductases, including ribonucleotide reductase, adenosine 3'-phosphate 5'-phosphosulfate reductase, methionine sulfoxide reductase, and glutathione peroxidase, accept electrons from both Trx and Grx (44). However, none of the Prx enzymes are able to receive electrons from Grx. These proteins therefore appear to provide the first instance in which the electron carrier functions of Trx and Grx can be distinguished.

To date, catalase and glutathione peroxidase have been viewed as the major enzymes responsible for removal of cytotoxic H2O2. Our data now suggest that Prx enzymes also might play a role in the removal of H2O2. In rat hepatocytes, catalase is largely or entirely localized to peroxisomes, whereas glutathione peroxidase is present in various intracellular compartments including mitochondria (42%), nuclei (26%), cytosol (21%), peroxisomes (7%), and lysosomes (4%) (45). Our immunoblot analysis indicates that glutathione peroxidase is present in much lower concentrations compared with Prx enzymes in most tissues except liver (data not shown). All three Prx enzymes are abundant in various rat tissues and in cultured cells. The sum of the three Prx enzymes in cultured cells amounts to 2-8 µg/mg soluble protein.3 Prx III appears to be localized in mitochondria, whereas Prx I and Prx II are cytosolic proteins.

Although H2O2 is generally considered a toxic by-product of respiration, increasing evidence suggests that the production of H2O2 might be an integral component of membrane receptor signaling. In mammalian cells, a variety of extracellular stimuli, including tumor necrosis factor-alpha (46, 47), PDGF (35), and EGF (36), induces a transient increase in the intracellular concentration of H2O2. Inhibition of this increase by N-acetyl cysteine or catalase prevents the protein tyrosine phosphorylation induced by PDGF or EGF (35, 36) as well as the activation of the nuclear factor NF-kappa B induced by TNF-alpha (37).

The transient nature of the receptor-mediated increase in intracellular H2O2 suggests that, in addition to its production, the rapid removal of this molecule is important for receptor signaling. Given that we have shown that Prx I and Prx II can remove H2O2 generated in response to growth factors and that Prx II can inhibit the activation of NFkappa B elicited by H2O2 or TNF-alpha , they likely participate in the signaling cascade of growth factor and TNF-alpha . Furthermore, Prx I and Prx II, which are abundant in cytosol, likely play an important role in eliminating H2O2 generated as a by-product of metabolism in the cytosol. These conclusions are consistent with the fact that Prx I and Prx II were discovered in connection with a variety of seemingly unrelated cellular processes such as proliferation, differentiation, natural killer cell activity, the response to oxidative stress, and osteoregulation (12-24).

    ACKNOWLEDGEMENTS

We thank Drs. Dong-Yan Jin and Kuan-Teh Jeang for providing NFkappa B reporter gene and for assistance with gel mobility shift assay.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Dept. of Biology, Chonnam National University, Kwangju 500-757, Korea.

Present address: Dept. of Biochemistry, Ajou University Medical School, Suwon 442-749, Korea

par Present address: Dept. of Food and Nutrition, Chonnam National University, Kwangju 500-757, Korea.

Dagger Dagger Present address: Dept. of Extramural Affairs, NHLBI, National Institutes of Health, Bethesda, MD 20892.

§§ To whom correspondence should be addressed: Bldg. 3, Rm. 122, National Institutes of Health, Bethesda, MD 20892. Tel.: 301-496-9646; Fax: 301-480-0357.

1 The abbreviations used are: TPx, thioredoxin peroxidase; TPx was previously referred to as thiol-specific antioxidant (TSA); Trx, thioredoxin; Prx, peroxiredoxin; Grx, glutaredoxin; PCR, polymerase chain reaction; TR, Trx reductase; GR, glutathione reductase; DCF, 2',7'-dichlorofluorescein; DCFH-DA, DCF diacetate; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; CAT, chloramphenicol acetyltransferase.

2 S. W. Kang and S. G. Rhee, unpublished data.

3 H. Z. Chae, H. J. Kim, and S. G. Rhee, unpublished data.

4 D.-Y. Jin and K.-T. Jeang, unpublished data.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Kim, K., Kim, I.-H., Lee, K. Y., Rhee, S. G., Stadtman, E. R. (1988) J. Biol. Chem. 263, 4704-4711[Abstract/Free Full Text]
  2. Kim, I.-H., Kim, K., and Rhee, S. G. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 6018-6022[Abstract]
  3. Chae, H. Z., Kim, I.-H., Kim, K., and Rhee, S. G. (1993) J. Biol. Chem. 268, 16815-16821[Abstract/Free Full Text]
  4. Yim, M. B., Chae, H. Z., Rhee, S. G., Chock, P. B., Stadtman, E. R. (1994) J. Biol. Chem. 269, 1621-1626[Abstract/Free Full Text]
  5. Chae, H. Z., Chung, S. J., and Rhee, S. G. (1994) J. Biol. Chem. 269, 27670-27678[Abstract/Free Full Text]
  6. Netto, L. E. S., Chae, H. Z., Kang, S.-W., Rhee, S. G., Stadtman, E. R. (1996) J. Biol. Chem. 271, 15315-15321[Abstract/Free Full Text]
  7. Chae, H. Z., Uhm, T. B., and Rhee, S. G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7022-7026[Abstract]
  8. Chae, H. Z., Robison, K., Poole, L. B., Church, G., Storz, G., Rhee, S. G. (1994) Proc Natl. Acad. Sci. U. S. A. 91, 7017-7021[Abstract]
  9. Rhee, S. G., and Chae, H. Z. (1994) Mol. Cells (Korea) 4, 137-142
  10. Jacobson, F. S., Morgan, R. W., Christman, M. F., Ames, B. N. (1989) J. Biol. Chem. 264, 1488-1496[Abstract/Free Full Text]
  11. Storz, G., Jacobson, F. S., Tartaglia, L. A., Norgan, R. W., Silveira, L. A., Ames, B. N. (1989) J. Bacteriol. 171, 2049-2055[Medline] [Order article via Infotrieve]
  12. Shau, H., Butterfield, L. H., Chiu, R., and Kim, A. (1994) Immunogenetics 40, 129-134[Medline] [Order article via Infotrieve]
  13. Yamamoto, T., Matsui, Y., Natori, S., and Obinata, M. (1989) Gene (Amst.) 80, 337-343[CrossRef][Medline] [Order article via Infotrieve]
  14. Prospéri, M.-T., Fervus, D., Karczinski, I., and Goubin, G. (1993) J. Biol. Chem. 268, 11050-11056[Abstract/Free Full Text]
  15. Lim, Y. S., Cha, M. K., Kim, H. K., Uhm, T. B., Park, J. W., Kim, K., Kim, I.-H. (1993) Biochem. Biophys. Res. Commun. 107, 279-285
  16. Lim, Y. S., Cha, M. K., Kim, H. K., Kim, I. H. (1994) Gene (Amst.) 140, 279-284[CrossRef][Medline] [Order article via Infotrieve]
  17. Ishii, T., Yamada, M., Sato, H., Matsue, M., Taketani, S., Nakayama, K., Sugita, Y., and Bannai, S. (1993) J. Biol. Chem. 268, 18633-18636[Abstract/Free Full Text]
  18. Kawai, S., Takeshita, S., Okazaki, M., Kikuno, R., Kudo, A., and Amann, E. (1994) J. Biochem. (Tokyo) 115, 641-643[Abstract]
  19. Watabe, S., Kohno, H., Kouyama, H., Hiroi, T., Yago, N., and Nakazawa, T. (1994) J. Biochem. (Tokyo) 115, 648-654[Abstract]
  20. Iwahara, S.-I., Satoh, H., Song, D.-X., Webb, J., Burlingame, A. L., Nagae, Y., Muller-Eberhard, U. (1995) Biochemistry 34, 13398-13406[Medline] [Order article via Infotrieve]
  21. Sauri, H., Butterfield, L., Kim, A., and Shau, H. (1995) Biochem. Biophys. Res. Comm. 208, 964-969[CrossRef][Medline] [Order article via Infotrieve]
  22. Watabe, S., Hasegawa, H., Takimoto, K., Yamamoto, Y., and Takahashi, S. Y. (1995) Biochem. Biophys. Res. Comm. 213, 1010-1016[CrossRef][Medline] [Order article via Infotrieve]
  23. Ishii, T., Kawane, T., Taketani, S., and Bannai, S. (1995) Biochem. Biophys. Res. Comm. 216, 970-975[CrossRef][Medline] [Order article via Infotrieve]
  24. Tsuji, K., Copeland, N. G., Jenkins, N. A., Obinata, M. (1995) Biochem. J. 307, 377-381[Medline] [Order article via Infotrieve]
  25. Tonissen, K. F., Robins, A. J., and Wells, J. R. F. (1989) Nucleic Acids Res. 17, 3973[Medline] [Order article via Infotrieve]
  26. Luthman, M., and Holmgren, A. (1982) Biochemistry 21, 6628-6633[Medline] [Order article via Infotrieve]
  27. Martinez-Galisteo, E., Padilla, C. A., Garcia-Alfonso, C., Lopez-Barea, J., Bárcena, J. A. (1993) Biochimie (Paris) 75, 803-809[Medline] [Order article via Infotrieve]
  28. Chu, F., Doroshow, J. H., and Esworthy, R. S. (1993) J. Biol. Chem. 268, 2571-2576[Abstract/Free Full Text]
  29. York, J. D., Saffitz, J. E., and Majerus, P. W. (1994) J. Biol. Chem. 269, 19992-19999[Abstract/Free Full Text]
  30. Ohba, M., Shibanum, M., Kuroki, K., and Nose, K. (1994) J. Cell Biol. 126, 1079-1088[Abstract]
  31. Schreck, R., and Baeuerle, P. A. (1994) Methods Enzymol. 234, 151-163[Medline] [Order article via Infotrieve]
  32. Jin, D.-Y., and Jeang, K.-T. (1997) Nucleic Acids Res. 25, 378-387
  33. Luthman, M., and Holmgren, A. (1982) J. Biol. Chem. 257, 6686-6690[Abstract/Free Full Text]
  34. Flohé, L., and Günzler, W. A. (1984) Methods Enzymol. 105, 114-121[Medline] [Order article via Infotrieve]
  35. Sundaresan, M., Yu, Z.-X., Ferrans, V., Irani, K., and Finkel, T. (1995) Science 270, 296-299[Abstract]
  36. Bae, Y. S., Kang, S. W., Seo, M. S., Baines, I. C., Tekle, E., Chock, P. B., Rhee, S. G. (1997) J. Biol. Chem. 272, 217-221[Abstract/Free Full Text]
  37. Schreck, R., Rieber, P., and Baeuerle, P. A. (1991) EMBO J. 10, 2247-2258[Abstract]
  38. Baeuerle, P. A., and Henkel, T. (1994) Annu. Rev. Immunol. 12, 141-179[CrossRef][Medline] [Order article via Infotrieve]
  39. Anderson, M. T., Staal, F. J. T., Gilter, C., and Herzenberg, L. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11527-11531[Abstract/Free Full Text]
  40. Baeuerle, P. A., and Baltimore, D. (1996) Cell 87, 13-20[Medline] [Order article via Infotrieve]
  41. Kretz-Remy, C., Mehlen, P., Mirault, M.-E., and Arrigo, A.-P. (1996) J. Cell Biol. 133, 1083-1093[Abstract]
  42. Deleted in proof
  43. Holmgren, A. (1985) Annu. Rev. Biochem. 54, 237-271[CrossRef][Medline] [Order article via Infotrieve]
  44. Holmgren, A. (1989) J. Biol. Chem. 264, 13963-13966[Free Full Text]
  45. Asayama, K., Yokoda, S., Dobashi, K., Hayashibe, H., Kawaoi, A., and Nakazawa, S. (1994) Histochemistry 102, 213-219[Medline] [Order article via Infotrieve]
  46. Meier, B., Radeke, H. H., Selle, S., Younes, M., Sies, H., Resch, K., and Habermehl, G. G. (1989) Biochem. J. 263, 539-545[Medline] [Order article via Infotrieve]
  47. Lo, Y. Y. C., and Cruz, T. F. (1995) J. Biol. Chem. 270, 11727-11730[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.